GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.

@article{Bueschenfelde2008GM1EO,
  title={GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.},
  author={Christian Meyer Zum Bueschenfelde and Yvonne Feuerstacke and Katharina S G{\"o}tze and Katrin Scholze and Christian Peschel},
  journal={Cancer research},
  year={2008},
  volume={68 13},
  pages={5414-22}
}
Immunotherapy with rituximab alone or in conjunction with chemotherapy has significantly improved the treatment outcome of B-cell lymphoma patients. Nevertheless, a subpopulation of patients does not respond to rituximab. The reason for treatment failure as well as the exact mechanism of action is still uncertain. The function of rituximab has long been associated with the partitioning of CD20 molecules to lipid microdomains. We now show that the extent of CD20 recruitment to lipid rafts… CONTINUE READING